Respirix

Respirix

Non-invasive Hemodynamic Monitoring

Non-invasive Hemodynamic Monitoring

Overview

Raised to Date: Raised: $1,300,226

Platform

SeedInvest

Start Date

11/23/2018

Close Date

08/13/2019

Min. Goal
$200
Max. Goal
$1,500,000
Min. Investment

$200

Security Type

Debt

SEC Filing Type

RegD 506(c)    Open SEC Filing

Status
Funded
Reporting Date

08/30/2019

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$4,963

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

San Francisco, California

Respirix is raising funds on SeedInvest through Reg D 506(c) raise. The company has developed a handheld and portable device for non-invasive monitoring of congestive heart failure (CHF) patients. The device, Cardiospire, acquires and analyses a subtle pressure wave called a cariogenic oscillation for low-cost and non-invasive patient care management. The algorithm then ascertains if the patient is approaching CHF even before they experience symptoms. Daniel Burnett and Evan Luxon founded Respirix in 2015. The current crowdfunding campaign has a maximum target of $1.5 million. The campaign proceeds will be used for growth and expansion.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Respirix on SeedInvest 2018
Platform: SeedInvest
Security Type: Debt

Follow company

Follow Respirix on SeedInvest 2018
No Public Offering Page

Buy Respirix's Deal Report

Warning: according to the close date for this deal, Respirix may no longer be accepting investments.

Respirix Deal Report

Get KingsCrowd’s comprehensive report on Respirix including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Respirix is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Respirix deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge